|   |
26839-75-8
|
|   |
C07
|
|   |
AA06
|
|   |
5478
|
|   |
APRD00229
|
|   |
C <sub>13</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> S
|
|   |
316421 G / Mol
|
|   |
60%
|
|   |
Hepatic : 80%
|
|   |
25-5 Hour s
|
|   |
Renal
|
|   |
C: ()
|
|   |
Prescription Only
|
|   |
Oral <br> Ophthalmic
|
|
is a non-selective Beta-adrenergic Receptor Blocker . In its oral form (Blocadren®), it is used to treat High Blood Pressure and prevent Heart Attack s, and occasionally to prevent Migraine headaches. In its Ophthalmic form (Timoptic®), it is used to treat open-angle and occasionally secondary Glaucoma .
The most serious possible side effects include cardiac Arrhythmia s and severe Bronchospasm s. Timolol can also lead to Fainting , Stroke , Congestive Heart Failure , Depression , Confusion , and Impotence .
- Children and Adults: Ophthalmic: Initial: 0.25% solution, instill 1 drop twice daily; increase to 0.5% solution if response not adequate; decrease to 1 drop/day if ---controlled; do not exceed 1 drop twice daily of 0.5% solution Adults: Oral:
- Hypertension: Initial: 10 mg twice daily, increase gradually every 7 days, usual dosage: 20-40 mg/day in 2 divided doses; maximum: 60 mg/day
- Prevention of myocardial infarction: 10 mg twice daily initiated within 1-4 weeks after infarction
- Migraine headache: Initial: 10 mg twice daily, increase to maximum of 30 mg/day
- Gel-forming solution, ophthalmic, as maleate (Timoptic-XE®): 0.25% (2.5 mL, 5 mL); 0.5% (2.5 mL, 5 mL)
- Solution, ophthalmic, as hemihydrate (Betimol®): 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains Benzalkonium Chloride ]
- Solution, ophthalmic, as maleate: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL) benzalkonium chloride
- Timoptic®: 0.25% (5 mL, 10 mL); 0.5% (5 mL, 10 mL) benzalkonium chloride
- Solution, ophthalmic, as maleate free (Timoptic® OcuDose®): 0.25% (0.2 mL);0.5% (0.2 mL) use
- Tablet, as maleate (Blocadren®): 5 mg, 10 mg, 20 mg
|